Syndax Pharmaceuticals
IPOHome - Syndax
Public · Waltham, United States · Founded 2005 · $152.6M raised
- Headquarters
- Waltham, Massachusetts
- Employees
- 51–200
- Founded
- 2005
- Business Model
- B2B
- Website
- syndax.com
- Total Funding
- $152.6M
- Last Round
- $80.0M Series CAug 2015
- Rounds
- 4
- Type
- Public
About
Syndax is a commercial-stage biopharma developing cancer therapies for acute leukemia. Revumenib (Revuforj) FDA-approved for KMT2Ar acute leukemia.
Summary
Syndax Pharmaceuticals is a Biotech company based in Waltham, United States, founded in 2005. It has raised $152.6M in total across 4 rounds, most recently a $80.0M Series C round in Aug 2015. Investors include Royalty Pharma, Delos Capital and Fidelity Management.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Nov 2024
Sign up to see all 6 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...